Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03433183
Recruitment Status : Not yet recruiting
First Posted : February 14, 2018
Last Update Posted : April 30, 2019
Sponsor:
Collaborators:
United States Department of Defense
AstraZeneca
Information provided by (Responsible Party):
Sarcoma Alliance for Research through Collaboration

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Not yet recruiting
  Estimated Primary Completion Date : September 2021
  Estimated Study Completion Date : September 2021